Item 8.01. Other Events.

On January 18, 2022, Kinnate Biopharma Inc. issued a press release announcing that the U.S Food and Drug Administration has cleared the company's Investigational New Drug application for KIN-3248, a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma and urothelial carcinoma. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d)     Exhibits.

Exhibit No.   Description

  99.1        Press Release dated January 18, 2022.

104           Cover page interactive data file (embedded within the inline
              XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses